

RECEIVED RECEIVED

09/110,376

-2-

DEC 8 2000 DEC 8 2000

In the Drawings:

TECH CENTER 1600/2900 CENTER 1600/2900

Approval of the Examiner is respectfully requested for the changes marked in red on the enclosed copy of Fig. 22.

In the Claims:

Claim 1 (twice amended). A method of predicting the lymphotropic metastatic potential of a solid non-lymphoid primary tumor, the method comprising obtaining a plurality of representative samples of the tumor and determining for at least one product selected from the group consisting of TCR β , CD3, CD4, CD8, and ZAP-70 the percentage of tumor cells of each of the samples which express said at least one product, wherein the metastatic potential of the tumor is predicted to be low when no tumor cells in all of the samples are detected to express said at least one product [and predicted to be high when a high percentage of the tumor cells in at least one of the samples are detected to express said at least one product].

REMARKS

As required by the Examiner, the specification has been amended to more clearly describe Figs. 22A and 22B separately, including a change to Fig. 22 to so indicate Figs. 22A and 22B as separate. Approval of the Examiner is therefore respectfully requested for the changes marked in red on the enclosed copy of Fig. 22 (now Figs. 22A and 22B).

Claim 1 has been rejected under 35 USC 112, second paragraph, on the basis that "high percentage of the tumor cells" is vague and indefinite, the Examiner stating that one cannot determine the metes and bounds of what the Applicant considers to be a high percentage.

Claim 1 has been amended to more clearly define what Applicant regards as the invention. As amended, claim 1 does not